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Objective: Studies about cartilage repair in the hip and infant chondrocytes are rare. The aim of our study
was to evaluate the use of infant articular hip chondrocytes for tissue engineering of scaffold-assisted
cartilage grafts.
Method: Hip cartilage was obtained from ﬁve human donors (age 1e10 years). Expanded chondrocytes
were cultured in polyglycolic acid (PGA)-ﬁbrin scaffolds. De- and re-differentiation of chondrocytes were
assessed by histological staining and gene expression analysis of typical chondrocytic marker genes.
In vivo, cartilage matrix formation was assessed by histology after subcutaneous transplantation of
chondrocyte-seeded PGA-ﬁbrin scaffolds in immunocompromised mice.
Results: The donor tissue was heterogenous showing differentiated articular cartilage and non-
differentiated tissue and considerable expression of type I and II collagens. Gene expression analysis
showed repression of typical chondrocyte and/or mesenchymal marker genes during cell expansion,
while markers were re-induced when expanded cells were cultured in PGA-ﬁbrin scaffolds. Cartilage
formation after subcutaneous transplantation of chondrocyte loaded PGA-ﬁbrin scaffolds in nude mice
was variable, with grafts showing resorption and host cell inﬁltration or formation of hyaline cartilage
rich in type II collagen. Addition of human platelet rich plasma (PRP) to cartilage grafts resulted robustly
in formation of hyaline-like cartilage that showed type II collagen and regions with type X collagen.
Conclusion: These results suggest that culture of expanded and/or de-differentiated infant hip cartilage
cells in PGA-ﬁbrin scaffolds initiates chondrocyte re-differentiation. The heterogenous donor tissue
containing immature chondrocytes bears the risk of cartilage repair failure in vivo, which may be possibly
overcome by the addition of PRP.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Repair and/or regeneration of articular cartilage defects is
challenging in orthopedic surgery. Articular lesions are associated
with e.g., pain, blocking, reduced mobility, and have been shown to
progress to severe degeneration and osteoarthritis1,2. Amongst: C. Kaps, TransTissue Tech-
. Tel: 49-(0)-30-915-403-75;
, christian.kaps@charite.de
s Research Society International. Pother surgical interventions like microfracture, osteochondral graft
transfer, and cell-free scaffold-assisted one-step cartilage repair
procedures, the autologous chondrocyte implantation (ACI) has
been shown to be safe and effective in the treatment of chondral
and osteochondral defects of the knee joint3e7. First generation ACI
using a periosteal ﬂap to cover the cartilage defect ﬁlled with a
suspension of expanded chondrocytes has shown good to excellent
clinical results in the long-term in at least 70% of patients. However,
periosteum covered ACI may be associated with delamination,
loosening of the transplant and tissue hypertrophy8,9. To overcome
these inherent disadvantages, second and third generation ACI
procedures favor the use of collagen sheets for covering the defect
or embedding the chondrocytes in resorbable scaffolds made ofublished by Elsevier Ltd. All rights reserved.
P.C. Kreuz et al. / Osteoarthritis and Cartilage 21 (2013) 1997e20051998collagen, hyaluronan or polymers like polyglycolic acid/polylactic
acid copolymers (PLGA)10e12. However, studies about regenerative
approaches for the repair of cartilage defects of the hip and
regenerative medicine therapeutic options for infant patients and
children are scarce.
Arthroscopic antegrade drilling of osteochondritis dissecans
(OD) lesions with intact cartilage of the medial femoral condyles
has been shown to induce a healing response in fourteen children
aged 12 years13. In a randomized clinical trial, Gudas and colleagues
compared the effectiveness of osteochondral autologous trans-
plantation (mosaicplasty) and the microfracture procedure for the
treatment of OD in the femoral knee joint of ﬁfty children aged 12e
18 years. At 4 years follow-up, osteochondral autologous trans-
plantation has been shown to be superior to microfracture treat-
ment, both treatment options improved the patients’ situation
compared to baseline, but osteochondral grafting showed less
failures than the microfracture treatment14. ACI has been shown to
be clinically effective in the treatment of large symptomatic
chondral defects of the distal femur in thirty-seven children (11e17
years), of which 23 children were subjected previously to at least
one cartilage repair procedure like e.g., marrow stimulation15.
A recent systematic review about reparative/regenerative sur-
gical interventions for the treatment of hip cartilage defects lists
microfracture treatment, ACI, mosaicplasty and osteochondral
allografting as being promising options for hip cartilage repair.
Although the studies are often case series or lack a control group,
the obtained good clinical results are encouraging, in particular
when taking limited treatment options into account16. Micro-
fracture treatment has been reported to produce ﬁbrocartilage and
excellent defect ﬁll in 27 out of 29 patients with full thickness
acetabular cartilage defects as assessed by second-look arthroscopy
after 17e36 months17,18. A controlled retrospective study including
30 patients with post-traumatic hip chondropathy (grade 3 and 4)
has shown that patients treated with polymer (PLGA) scaffold-
assisted ACI signiﬁcantly improved better than patients treated
with debridement as assessed by Harris Hip Score at a follow-up of
72e76 months19.
The versatility and clinical effectiveness of polymer scaffolds for
chondrocyte-based repair of cartilage defects of the knee and the
hip in adults10,19,20 encouraged us to carry out the current study.
The aim was to evaluate the chondrogenic capacity of expanded
juvenile hip cartilage-derived cells in PGA-ﬁbrin scaffolds as a ﬁrst
step toward the use of expanded autologous infant chondrocytes in
PGA-ﬁbrin scaffolds for the treatment of cartilage defects in infant
and/or juvenile patients. We wanted to ﬁgure out, if subcutaneous
transplantation of PGA-ﬁbrin scaffolds loaded with expanded in-
fant hip cartilage cells in athymic mice leads to ectopic formation of
cartilage. Here we show that e due to the heterogeneity of
immature infant hip cartilage, echondrocyte redifferentiation was
accompanied by the re-induction of ﬁbrocartilage and hypertrophy
marker molecules like types I and X collagen. Results after subcu-
taneous transplantation were variable ranging from failure to
ectopic cartilage tissue formation in immunocompromised nude
mice. The varying results could be overcome by the addition of
platelet-rich plasma (PRP), which resulted reproducibly in ectopic
cartilage formation with presence of type II collagen, but ‘hyper-
trophic’ areas with type X collagen.
Methods
Isolation and cultivation of human infant hip chondrocytes
Chondrocytes were obtained from infant and juvenile human
donors (two girls, three boys, age 1e10, mean 3 years) with hip
dysplasia (n ¼ 4) and Perthes disease (n ¼ 1). Slices of cartilagewere digested for 4e6 h at 37C in Roswell Park Memorial Institute
(RPMI) 1,640 medium (Biochrom, Germany) containing antibiotics
(100 U/ml penicillin, 100 mg/ml streptomycin, 100 mg/ml genta-
micin, 0.1 mg/ml amphotericin (all Biochrom, Germany)), 10% hu-
man serum (German Red Cross, Germany), 1.5 U/ml collagenase P
(Boehringer-Mannheim, Germany), 500U/ml collagenase type CLS
II (Seromed, Germany) and 50 U/ml hyaluronidase (Sigma, Ger-
many) as described21. Chondrocytes were plated at 10,000 cells/
cm2 and cultured in RPMI supplemented with 10% human serum
and antibiotics at 37C, 5% CO2, and 95% humidity. On reaching 80%
conﬂuence, cells were trypsinized and subcultured up to passage 3,
plating 10,000 cells/cm2. The culture medium was replaced every
other day. The study was approved by the ethical committee of the
University Medical Center Rostock (Ref. No.: A2011 31).
Three-dimensional chondrocyte cultures
For assembly in resorbable PGA scaffolds (n ¼ 6 per donor,
n ¼ 30 in total), chondrocytes (passage 3) were trypsinized and re-
suspended in ﬁbrinogen (33% v/v ﬁbrinogen (Tissucol, Baxter,
Germany) in RPMI medium containing 10% human serum) at a cell
density of 2.4  107 cells/ml. PGA scaffolds (BioTissue AG,
Switzerland) were immersed with the chondrocyte-ﬁbrinogen
suspension, and ﬁbrinogen was polymerized by addition of
thrombin (1:10 v/v in phosphate-buffered saline (PBS); Tissucol,
Baxter, Germany). Chondrocyte grafts were cultured in RPMI me-
dium supplemented with 5% human serum, 50 mg/ml ascorbic acid,
100 U/ml penicillin and 100 mg/ml streptomycin. The medium was
replaced every other day.
Immunohistochemistry
Cryosections (8 mm) of native tissue and PGA-ﬁbrin chondrocyte
grafts were prepared and stained with safranin O, alcian blue (pH
2.5) or toluidine blue (n ¼ 5 donors). Viability of grafts was shown
by ﬂuorescein diacetateepropidium iodide (FDAePI) staining22. For
immunohistochemistry, cryosections (6 mm) were digested for
30 min with 1 mg/ml hyaluronidase (Sigma, Germany) in PBS, fol-
lowed by incubation for 1 h with primary antibodies (rabbit anti-
human type I, II collagens (Acris, Germany) and type X collagen
(Abbiotec, USA.)). Rabbit IgG served as control (DAKO, Germany).
Detection was performed according to the manufacturer’s in-
structions using the EnVisionþþ System HRP (AEC) Kit (DAKO) and
counterstaining with hematoxylin.
For histological analysis of in vivo matured cartilage grafts, ex-
plants (n ¼ 6) were ﬁxed in 4% formaldehyde in PBS, dehydrated in
ethanol, and parafﬁn-embedded. Cross-sections (5 mm) were de-
waxed and stained with toluidine blue for detection of sulfated
glycosaminoglycan. For immunohistochemical analysis, sections
were treated with methanol:H2O2 (49:1) for 30 min, with 1 mg/ml
hyaluronidase in PBS pH 6.0, for 30 min at 37C, and goat serum for
1 h. Anti-type II collagen (CIICI anti-COLLII, DSHB, University of
Iowa) or anti-type X collagen antibodies (Quartett, Germany) were
added for 1 h at room temperature. For detection, biotinylated
secondary antibodies and streptavidin-peroxidase (Histomouse
Kit; Zymed Laboratories, USA) followed by incubation with AEC
chromogen substrate (Sigma, Germany) was used. Stained slides
were observed at different magniﬁcations and images were ac-
quired with the Axiovert 200 M microscope (Carl Zeiss, Germany).
Polymerase chain reaction (PCR)
Total RNA (n ¼ 5 donors) was isolated from native cartilage,
expanded chondrocytes (passage 1 and 3) as well as from chon-
drocytes that were cultured in PGA-ﬁbrin scaffolds for 1, 2 and 3
Table I
Oligonucleotide sequences
Gene name Accession
no.
Oligonucleotides (50 / 30), (up/down) Base
pairs
Type I collagen NM_000088 CGA TGG CTG CAC GAG TCA CAC/
CAG GTT GGG ATG GAG GGA GTT TAC
180
Type II collagen NM_001844 CCG GGC AGA GGG CAA TAG CAG GTT/
CAA TGA TGG GGA GGC GTG AG
128
Type IX collagen NM_001853 AAT CAG GCT CTC GAA GCT CAT AAA A/
CCT GCC ACA CCC CCG CTC CTT CAT
100
Type X collagen NM_000493 GAA CTC CCA GCA CGC AGA ATC C/
GTG TTG GGT AGT GGG CCT TTT ATG
145
Cartilage
oligomeric
matrix protein
NM_000095 CCG GAG GGT GAC GCG CAG ATT GA/
TGC CCT CGA AGT CCA CGC CAT TGA A
133
Aggrecan NM_001135 GGC TGC TGT CCC CGT AGA AGA/
GGG AGG CCA AGT AGG AAG GAT
163
Glyceraldehyde-
3-phospate
dehydrogenase
NM_002046 GGC GAT GCT GGC GCT GAG TAC/
TGG TCC ACA CCC ATG ACG A
149
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the iScript cDNA Synthesis Kit according to the manufacturer’s in-
structions (BioRad). The relative expression level of the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used to normalize samples. Real-time PCR using the i-Cycler
PCR System (BioRad) was performed with 1 ml of cDNA sample
using the SYBR Green PCR Core Kit (Applied Biosystems) in tripli-
cates. Relative quantitation of marker gene expression (Table I) was
performed and is given as percentage of the GAPDH product as
reported previously21. Differential expression (fold change, FC) of
marker genes was calculated according to the DDCt method24.
Ectopic cartilage formation in athymic mice
Prior to mice transplantation assays, the chondrogenic potential
of expanded infant chondrocytes (passage 2) was investigated by
the micromass pellet culture (n ¼ 3 donors). 2.5  105 cells were
pelleted in 15 ml conical tubes and cultured for 21 days in chon-
drogenic medium (10 ng/ml hTGF-B1 (Peprotech), 107 M dexa-
methasone (Sigma) and 50 mg/ml ascorbic acid (Sigma)) as
described25. Medium was changed every two days. Cartilage for-
mation was evaluated by toluidine staining.Fig. 1. Immunohistochemical analysis of human infant hip cartilage tissue. Hip cartilage tiss
slides per donor) and alcian blue staining (B), n ¼ 3 donors, n ¼ 3 slides per donor), collage
tissue) and collagen type I (D), n ¼ 3 donors, n ¼ 3 slides per donor). There was no collagen
showed speciﬁcity of the antibody staining (F), n ¼ 3 donors, n ¼ 3 slides per donor). Orientat
types I, II and X for each individual donor tissue as well as age and sex of donors is givenChondrocytes (passage 2, n ¼ 3 donors) were loaded with ﬁbrin
(Tissucol) in PGA scaffolds and used for subcutaneous implantation
in athymic mice (CD-1 nu/nu; Charles River Italia, Italy). PGA scaf-
foldswere soakedwith 300ml of PRP or PBS and lyophilized. PRPwas
prepared as described26. In brief, PRP was obtained from healthy
human blood donors at the Blood Transfusion Center of the San
Martino Hospital, Genova, Italy, according to the protocol approved
by the institutional ethics committee. After serial centrifugations,
the platelet pellet was resuspended in plasma at a concentration of
about 107 platelets/ml. After that, 2.5  106 human chondrocytes
were loaded on the scaffolds and implanted in nude mice. All ani-
mals were maintained in accordance with the standards of the
Federation of European Laboratory Animal Science Associations
(FELASA). Animals were sacriﬁced, and implants were harvested
after 4 weeks to evaluate cartilage formation by histology.Statistical analysis
For analysis of differential expression, the t-test was applied in
normal distributed expression data, while theManneWhitney rank
sum test was used for non-normal distributed data. Normal dis-
tribution of data was tested using the KolmogoroveSmirnov
method. The SigmaStat 3.5 software (Systat Software Inc, USA.) was
used. Expression data with a fold change (FC) of 2 or >2 were
considered differentially expressed. Differences were considered
signiﬁcant at P < 0.05. The 95% conﬁdence interval (CI) was
calculated and the upper/lower limit is given.Results
Heterogeneous cartilage matrix in native infant cartilage
Histological staining of infant articular cartilage of the hip
(Fig. 1) showed a homogeneous and intense staining of safranin O
[Fig. 1(A)] and alcian blue [Fig. 1(B)], indicating abundant amounts
of proteoglycan. Type II collagen [Fig. 1(C)] was evident in outer and
superﬁcial regions of the cartilage (asterisk), while deeper regions
showed no type II collagen (pound). Type I collagen was absent in
superﬁcial regions but showed pronounced staining in deeper re-
gions [Fig. 1(D)]. There was no type X collagen evident [Fig. 1(E)].ue specimens showed proteoglycans as assessed by safranin O (A), n ¼ 3 donors, n ¼ 3
n type II (C), n ¼ 3 donors, n ¼ 3 slides per donor; * e cartilage, # e undifferentiated
type X present (E), n ¼ 3 donors, n ¼ 3 slides per donor). Controls gave no signal and
ion: top e superﬁcial zone/cartilage surface. Staining of safranin O, alcian blue, collagen
in the supplemental material (Supplemental Fig. 1).
Fig. 2. Cell culture and growth of human infant hip chondrocytes. Hip cartilage-
derived cells/chondrocytes showed a typical ﬁbroblastic appearance of dediffer-
entiated chondrocytes when expanded in monolayers (A). Growth kinetics were
measured up to passage 7 and showed continuous growth of infant hip chondrocytes
(B). Cell numbers are given for each individual cell preparation (n ¼ 5).
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of the antibody staining [Fig. 1(F)]. Gene expression analysis of
typical chondrocytemarker genes showed robustly high expression
of types II and IX collagen, moderate expression of cartilageFig. 3. Immunohistochemical analysis of expanded human infant hip chondrocytes embedd
PGA-ﬁbrin scaffolds for 3 weeks, cells formed an extracellular matrix with collagens and
preparation; black arrow heads) and alcian blue staining (B), n ¼ 5 cell preparations, n ¼ 3 sli
and degrade (A, black double arrow heads). The tissue showed no collagen types II (C), n ¼ 5
slides per preparation). Collagen type I (D), n ¼ 5 cell preparations, n ¼ 3 slides per prepar
chondrocytes in PGA-ﬁbrin scaffolds (F), n ¼ 5 cell preparations, n ¼ 1 staining per prepar
donor-derived cell preparation as well as age and sex of donors is given in the supplemenoligomeric matrix protein (COMP) and low levels of aggrecan
(ACAN). Expression of type I collagen was high, and 4 out of 5
cartilage tissue samples showed a considerable expression level of
type X collagen (Supplemental material Fig. 1).
Culture of expanded infant chondrocytes in PGA-ﬁbrin scaffolds
For the preparation of chondrocyte-seeded PGA-ﬁbrin scaffolds,
chondrocytes were harvested by enzymatic digestion of the carti-
lage matrix and expanded using conventional cell culture condi-
tions. Within 2e3 days, the cells attached to the plastic surface of
the cell culture plate, began to stretch and developed the shape of
elongated, ﬁbroblast-like cells. Sub-cultivated cells showed a stable
ﬁbroblastic morphology [Fig. 2(A)] and a stable and high prolifer-
ation capacity up to at least passage 7 [Fig. 2(B)]. The growth ki-
netics showed that infant chondrocytes reached cell numbers from
0.24  106 to 0.90  106 cells in passage 1 up to 3.54  107 to
1.16  1010 cells after a cultivation time of 28 days. The population
doubling time was 25.6  7.2 h.
Histological analysis of invitro formed tissuewasperformedafter
3 weeks of tissue culture of expanded infant chondrocytes in PGA-
ﬁbrin scaffolds (Fig. 3). The cells were embedded in an extracel-
lular matrix [Fig. 3(A), black arrows] ﬁlling the space between the
PGA ﬁbers. PGA ﬁbers started to degrade and showed a fragmented
appearance [Fig. 3(A), black double arrow]. The extracellular matrix
showed a weak staining of collagens [Fig. 3(A), greenish color] and
proteoglycans [Fig. 3(B)], as assessed by safranin O and alcian blue
staining. Immunostaining showed absence of type II [Fig. 3(C)] and
typeX [Fig. 3(E)] collagen,while stainingof type I collagen [Fig. 3(D)]
was evident.Viability stainingdocumented that thecellswereviable
and evenly distributed within the PGA-ﬁbrin scaffolds over the tis-
sue culture period of 3 weeks [Fig. 3(F)].
Gene expression analysis of expanded infant chondrocytes cultured
in PGA-ﬁbrin scaffolds
To conﬁrm dedifferentiation of infant chondrocytes during
expansion and chondrogenic re-differentiation in PGA-ﬁbrin scaf-
folds, semi-quantitative gene expression analysis of genes encodinged in PGA-ﬁbrin scaffolds. After culture of expanded infant hip-derived chondrocytes in
proteoglycans as assessed by safranin O (A), n ¼ 5 cell preparations, n ¼ 3 slides per
des per preparation), while the PGA ﬁbers of the resorbable scaffold started to fragment
cell preparations, n ¼ 3 slides per preparation) and X (E), n ¼ 5 cell preparations, n ¼ 3
ation) was evident. Viability staining with FDAePI proofed high viability of infant hip
ation. Staining of safranin O, alcian blue, collagen types I, II and X for each individual
tal material (Supplemental Fig. 2).
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Compared to morphologically full de-differentiated, expanded
chondrocytes (passage 3), native hip cartilage showed signiﬁcantly
increased gene expression levels of all hyaline cartilage matrix
marker molecules like types II and IX collagen, COMP and ACAN.
Interestingly, the expression level of type I collagen being a marker
for ﬁbrocartilage or undifferentiated mesenchymal tissue and type
X collagen being a marker for hypertrophic chondrocytes were
signiﬁcantly increased (25.5 fold/2.9Eþ5 fold) in native hip carti-
lage compared to dedifferentiated chondrocytes.
Tissue culture of expanded infant hip chondrocytes in PGA-
ﬁbrin scaffolds up to 3 weeks resulted in signiﬁcant induction
and/or re-expression of cartilage marker genes type II collagen (up
to 34.1 fold), type IX collagen (6.8 fold), and COMP (up to 59.6 fold)
compared to marker gene expression in expanded chondrocytes
(passage 3). ACAN was signiﬁcantly repressed at day 7e14 in tissue
culture compared to expanded monolayer chondrocytes, but
showed increased expression levels in chondrocytes after pro-
longed culture in PGA-ﬁbrin scaffolds at day 21 (2.0 fold). Type I
collagen expression was signiﬁcantly induced up to 4.8 fold, and
expression of type X collagenwas signiﬁcantly increased up to 26.4
fold in PGA-ﬁbrin scaffolds, compared to expanded chondrocytes.
Ectopic cartilage formation by PGA-ﬁbrin scaffolds seeded with
expanded infant chondrocyte
Toluidine blue staining of pellet cultures made from infant
chondrocytes showed that the chondrogenic capacity of the indi-
vidual cell preparations was variable, showing metachromatic
staining of the pellet [Fig. 5(A) and (B)] or weak metachromasy in
the outer, superﬁcial zone of the pellets [Fig. 5(C), white arrows].
Consequently, ectopic cartilage tissue formation by chondrocyte-
seeded PGA-ﬁbrin scaffolds after subcutaneous transplantationFig. 4. Real-time gene expression analysis of expanded human infant hip chondrocytes em
marker genes such as ACAN, COMP, type II and type IX collagen was calculated as fold
chondrocytes (passage 3). For chondrocyte hypertrophy, the expression level of type X coll
ferentiated mesenchymal tissue. The mean expression value (n ¼ 3) is plotted, the red bar
represent 95% CI. Asterisk, signiﬁcantly (P < 0.05) different compared to expression level fou
(male, 10 years), : donor 3 (female, 20 months), B donor 4 (male, 12 months), * donor 5into nude mice was variable. Individual cell preparations showed
formation of cartilaginous tissue [Fig. 5(D), asterisk] with remnants
of the PGA ﬁbers [Fig. 5(D), white arrow], were completely resor-
bed, showed inﬁltration of host cells [Fig. 5(D), black arrows] or
newly formed cartilage tissues with a matrix rich in type II collagen
[Fig. 5(E)]. The cell preparation that showedweakmetachromasy in
pellet culture failed to form cartilage tissue in vivo and was
completely inﬁltrated by host cells and resorbed [Fig. 5(F)]. The
variability of individual cell preparations in PGA-ﬁbrin scaffolds to
form new cartilage tissue could be overcome by the addition of PRP.
The same preparations of expanded infant chondrocytes seeded in
PGA-ﬁbrin scaffolds immersed with PRP showed ectopic formation
of cartilage tissue with marginal host cell inﬁltration and a meta-
chromatic extracellular matrix [Fig. 5(G)] rich in type II collagen
[Fig. 5(H)]. Interestingly, type X collagen was evident in some areas
of the newly formed cartilage tissue [Fig. 5(I), black arrows].
Discussion
In the present study, we have shown that human infant hip
cartilage is a heterogeneous tissue showing mature chondrocytes,
undifferentiated mesenchymal cells and/or immature chon-
drocytes. Three-dimensional assembly of expanded hip chon-
drocytes in PGA-ﬁbrin scaffolds initiates re-differentiation of cells
that is accompanied by induction of typical chondrocyte and
mesenchymal marker genes like type II collagen and COMP.
However, ectopic formation of cartilage after subcutaneous
transplantation of PGA-ﬁbrin scaffolds loaded with expanded hip
cartilage cells was variable leading to proper cartilage formation
or complete failure with resorption of the graft. The variable
outcome has been overcome by addition of human PRP that
resulted in robust formation of ectopic cartilage in the mice
model.bedded in PGA-ﬁbrin scaffolds. The gene expression proﬁle of typical chondrogenic
change compared to the gene expression level found in expanded, de-differentiated
agen was measured. Type I collagen was chosen as marker for ﬁbrocartilage or undif-
represents the mean of all expression values (n ¼ 5 donors) and the grey/white bars
nd in expanded chondrocytes (passage 3).A donor 1 (female, 12 months),- donor 2
(male, 3 years).
Fig. 5. Ectopic cartilage formation after subcutaneous transplantation of expanded human infant hip chondrocytes embedded in PGA-ﬁbrin scaffolds in the mouse model. Prior to
transplantation, the cartilage formation potential of expanded infant hip chondrocytes was tested using pellet culture (AeC), n ¼ 3 cell preparations, n ¼ 2e4 pellets per prep-
aration). Toluidine blue showed metachromatic staining throughout the pellet (A,B) or weak metachromasy in the outer zone (C, white arrow heads). Four weeks after trans-
plantation, grafts that were not augmented with PRP (n ¼ 3 cell preparations; n ¼ 1 graft per preparation) showed variable formation of ectopic cartilage (DeF). Hematoxylin
staining showed cartilaginous tissue (D, asterisk), ingrowth of ﬁbroblastic host cells (D, black arrow heads) and remnants of ﬁbers of the PGA scaffold (D, white arrow heads). Type II
collagen staining proofed ectopic formation of cartilage tissue (E). One out of three grafts failed to form cartilaginous tissue and was completely resorbed (F). The addition of PRP
(n ¼ 3 cell preparations; n ¼ 1 graft per preparation) resulted in the formation of ectopic cartilage that showed metachromatic staining with toluidine blue (G) and a matrix rich in
type II collagen (H). In some regions of the newly formed cartilage type X collagen was evident (I, black arrow heads). Staining of hematoxylin, toluidine blue, collagen types II and X
for each individual donor-derived cell preparation with and without the addition of PRP as well as age and sex of donors is given in the supplemental material (Supplemental Fig. 4).
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adult donors are accompanied by the loss of their chondrocyte
phenotype and by a fundamental change of the chondrocyte gene
expression proﬁle with repression of typical chondrocyte marker
genes like type II collagen and induction of undifferentiated
mesenchymal tissue or ﬁbroblast-related genes like type I collagen.
Re-differentiation of expanded dedifferentiated adult chondrocytes
in e.g., scaffolds is characterized by re-induction of chondrocyte
markers and maintenance of high levels or repression of the
ﬁbroblast-related marker type I collagen27e31. Infant hip cartilage
and chondrocytes showed high levels of typical chondrocyte
markers like type II collagen and remarkably high levels of types I
and X collagen. In contrast to the expression proﬁles found in adult
chondrocytes, the level of e.g., type I collagen decreased during
expansion of infant hip cartilage-derived cells and embedding the
chondrocytes in PGA-ﬁbrin scaffolds resulted in re-induction of
type I collagen. This is a similar proﬁle found for type II collagen
being a key marker for mature cartilage in infants and adults. These
expression proﬁles may indicate heterogeneity of the donor tissue
with at least mature cartilage and immature, undifferentiated
mesenchymal tissue as well as hypertrophic chondrocytes and/or
cartilage. Although immune-staining of infant hip cartilage for type
X collagen was negative, the high gene expression level may be
indicative for chondrocyte hypertrophy32. However, assembly of
expanded infant chondrocytic hip cells in PGA-ﬁbrin scaffolds and
subsequent in vitro tissue culture resulted in the re-induction of
chondrocyte marker genes as well as types I and X collagen.Obviously, three-dimensional re-arrangement of expanded infant
hip cells in resorbable scaffolds initiates cartilaginous re-
differentiation of the dedifferentiated cells. This is in line with the
capacity of adult dedifferentiated articular chondrocytes to re-
express the chondrocyte phenotype when cultured in resorbable
scaffolds made from PGA, PLGA copolymers or hydrogel-polymers
like alginate or hyaluronan27,33e36.
Initiation of chondrocyte re-differentiation and subsequent
maturation of the tissue toward cartilage in vivo after trans-
plantation accompanied by the timely degradation and resorption
of the polymer-based scaffold that ensures initial mechanical sta-
bility of the graft has been shown to “work” in adult knee chon-
drocytes using PGA, PLGA or polymer scaffolds in a variety of
animal models35,37e39. As shown here for juvenile chondrocytes,
tissue formation in vivo in the absence of PRP was variable and
showed failures. Since the cell preparation that failed to form
cartilage tissue in vivo in the absence of PRP showed a reduced
chondrogenic potential in the in vitro pellet assay and since the
scaffold batch performed well when other individual cell prepa-
rations were used, it is most likely that the failure is donor-related,
probably due to lack of chondrogenesis or cell death. The variable
potential of expanded infant hip chondrocytes to form cartilage
in vivo may due to the lack of differentiation or maturation pro-
moting factors, excessive expansion/de-differentiation of cells
probably accompanied by the loss of their re-differentiation ca-
pacity and/or ‘cartilage memory’ as well as the presence of imma-
ture, undifferentiated mesenchymal cells. Since mechanical stimuli
P.C. Kreuz et al. / Osteoarthritis and Cartilage 21 (2013) 1997e2005 2003play a key role in e.g., cartilage development, homeostasis and
tissue engineering40, the lack of biomechanical forces in the sub-
cutaneous environment is a limitation of the in vivo differentiation
mouse model and may account for the variability in cartilage tissue
formation by infant chondrocytes.
However, the mixture of juvenile cartilaginous cells and undif-
ferentiated mesenchymal stem cells has been shown to have a
chondrogenesis promoting effect, in vitro. Pellets of stem cells
encased within a layer of juvenile chondrocytes (<13 years of age)
and juvenile chondrocyte pellets showed higher expression levels
of chondrocyte marker genes and less types I and X collagen than
pellets of pure stem cells41. This suggests that at least juvenile
chondrocytes have a differentiation promoting potential on
immature, undifferentiated mesenchymal cells. Expanded infant
hip chondrocytes, probably mixed with immature, undifferentiated
mesenchymal cells failed to robustly form cartilage tissue after
transplantation into nude mice. This differentiation promoting
potential of chondrocytes on immature mesenchymal cells may be
dependent on age (infantejuvenile) or the maturation and/or dif-
ferentiation status of the donor chondrocyte (immatureemature).
In addition, the behavior of infant chondrocytes in terms of clinical
efﬁcacy or even superiority to adult chondrocytes for cartilage
repair is unknown. Adolescent chondrocytes (12e18 years of age) in
ACI have been shown to reduce pain and improve postoperative
function in this patient group42,43. Therefore, it is suggested that an
autologous ACI approach for cartilage repair in children is safe,
feasible and effective. The cartilage autograft implantation system
(CAIS) procedure with adult cartilage has been shown to be a safe
and effective method for cartilage repair that may perform better
than the microfracture procedure according to the International
Knee Documentation Committee (IKDC) score44. Clinical experi-
ence with the DeNovo NT procedure that uses allogenic cartilage
derived from children is still limited with short-term studies and
case reports showing promising results45,46. Pre-clinical in vitro
studies have shown that juvenile chondrocytes grow better and
show elevated levels of chondrocyte markers compared to adult
chondrocytes, suggesting that they have a greater potential to
restore articular cartilage than adult chondroctyes47. In addition,
juvenile chondrocytes may beneﬁcial for cartilage repair by stim-
ulating matrix synthesis of adult chondrocytes as shown in three-
dimensioanl agarose cultures48. However, prospective random-
ized trials and/or comparative trials are needed to show that
cartilage repair with juvenile cartilage or chondrocytes is clinically
effective or even better than repair with adult chondrocytes.
The variable potential of expanded infant hip chondrocytes in
forming of cartilaginous tissue in nude mice could be overcome by
the addition of PRP. PRP is known as a cocktail of autologous growth
factors, cytokines and chemokines released by alpha granules of
platelets49e51. The data about PRP effects on chondrocytes and
mesenchymal stem cells are conﬂicting. PRP or platelet supernatant
has been shown to stimulate proliferation of adult articular knee
chondrocytes from different species, while there was no effect on
chondrocyte differentiation52e54. Interestingly, in human mesen-
chymal stem cells or subchondral progenitor cells, PRP induces the
proliferation of stem cells in monolayer cultures55, induces the
osteogenic and chondrogenic marker transcription factors Runx2
and Sox9 in monolayer56 and promotes chondrogenic but not
osteogenic or adipogenic differentiation of human subchondral
progenitor cells in pellet cultures57. In pre-clincial and clinical stem
cell based applications, PRP has been shown to stimulate cartilage
repair after microfracture in the ovine model58 and to regenerate
cartilaginous tissue and to improve the patients’ situation at one to
two year follow-up according to the Knee Injury and Osteoarthritis
Outcome Score (KOOS), when combined with bone marrow-cells
and a hyaluronan scaffold59 or a cell-free PGA-hyaluronanscaffold5,60. Therefore, in our differentiation system using PGA-
ﬁbrin scaffolds and subcutaneous mice transplantation assays, we
suggest that the addition of PRP to expanded infant hip chon-
drocytes cultures that may a mixed population of mature chon-
drocytes and undifferentiated/immature mesenchymal cells, may
improve cartilage formation in vivo by inducing chondrogenic dif-
ferentiation of immature, undifferentiated cells and/or by stimu-
lating chondrogenesis of expanded hip chondrocytes. This
heterogeneity reducing or minimizing effect of PRP being a source
of autologous growth factors is in line with a recent study that
showed that adding transforming growth factor-b1 may reduce the
variability of chondrogenic differentiation in expanded adult
chondrocytes61. However, future studies using preparations of
mature infant hip chondrocytes, undifferentiated subchondral
mesenchymal cells and immature chondrocytes are needed to
elucidate the chondrogenic and heterogeneity minimizing effect of
PRP on infant hip-derived cells. A further limitation of the study is
the lack of biomechanical/functional data showing that the newly
formed repair tissue may fulﬁll physiological demands in cartilage
repair. Before applying tissue engineered infant hip chondrocyte
grafts clinically, at least further studies addressing cartilage repair
in large animal hip joint defect models and the impact of PRP on
pure mature hip chondrocytes and immature subchondral cells are
needed.
In summary, human expanded infant hip chondrocytes or infant
hip-derived cells embedded in PGA-ﬁbrin scaffolds have the po-
tential to redifferentiate accompanied by the re-induction of typical
chondrocyte marker genes in vitro and form cartilaginous repair
tissue in vivo, even ectopically as shown in the subcutaneous mice
transplantation model. The tissue heterogeneity of infant hip
chondrocytes showing immature, undifferentiated mesenchymal
cells and chondrocytes bears the risk of cartilage formation failure.
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